These findings highlighted the potential of CHSY3 as a target for therapeutic intervention in IDD and suggested that low-dose celecoxib might help prevent or treat IDD by targeting CHSY3. This evidence concerns the gene CHSY3 and intervertebral disk degenerative disorder.